Ritonavir, an inhibitor of the HIV protease enzyme, is one of the most potent drugs available for the treatment of patients with HIV infection [ 1] . Preliminary data suggest the administration of ritonavir to patients with advanced disease may result in a significant reduction in mortality [2] . The current recommended dose, 600 mg twice daily, has been demonstrated to produce a viral load reduction of −2.0 log 10 ( by RNA PCR) which was sustained at −0.81 log 10 by 32 weeks [3 ] . This was associated with an increase in the CD4 count of 230 cells/mm3 above pretreatment levels. We report our experience with this new anti-HIV agent and 600 mg twice daily over the past 12 weeks. There were 48 adverse events reported by 12 of the patients (70%).
concentration thereby maintaining anti-viral efficacy. In In five patients these adverse effects were so severe as our clinical experience the main problems associated to result in the discontinuation of ritonavir therapy with ritonavir use are patient tolerability and drug (29%). The most frequent adverse effects included interactions resulting from the potent enzyme inhibiting nausea (severe, grade 3 in six patients), vomiting properties of the drug. A change in dose schedule to (moderate, grade 2 in three patients), perioral and 300 mg 6 hourly may not influence potential drug peripheral paraesthesae (moderate, grade 2 in two interactions but should improve the tolerability of patients) and malaise (moderate, grade 2 in four ritonavir enabling patients to benefit from one of the patients). Other adverse effects reported included throat most potent anti-HIV drugs available. irritation, myositis, pyrexia, stomatitis and insomnia. Two patients lost 3 kg in weight during ritonavir therapy C. MERRY1,2, M. BARRY1, S. GIBBONS1, and recovered this on cessation. Of those patients F. MULCAHY2 & D. BACK1 reporting adverse effects, over 70% indicated the onset 1Department of Pharmacology and T herapeutics, of symptoms 2 h after each dose and lasting for University of L iverpool, PO Box 147, L iverpool, L 69 3BX approximately 4 h. In two patients who wished to and 2Department of Genitourinary Medicine, discontinue ritonavir treatment we altered the dose St James's Hospital, Dublin, Ireland regimen to 300 mg every 6 h in view of the apparent relationship between dosing and adverse effects and a (Received 4 July 1996, knowledge of the pharmacokinetics of ritonavir which accepted 29 July 1996 ) has a very short elimination half-life of 3 h. This alteration was associated with a resolution in symptoms References enabling these two patients to continue taking ritonavir.
Mindful of the fact that the 90% effective plasma
